Merck Reports Q3 2026 Earnings and Updates Full-Year Outlook
Merck & Co., Inc.
Subscribe to track MRK
Premium users can add ticker alerts and receive realtime notification updates.
Filing Summary
Merck & Co., Inc. (NYSE: MRK) filed an 8-K reporting Q3 2026 financial results under Item 2.02. Total worldwide sales reached $18.09 billion (up 5% year-over-year), driven by KEYTRUDA ($8.60 billion, +6%) and WINREVAIR ($694 million, +93%). GAAP EPS was $2.04 and Non-GAAP EPS was $2.49. Merck narrowed and raised its full-year 2026 sales guidance to $66.8B–$67.3B and Non-GAAP EPS guidance to $2.77–$2.82.
Comprehensive Analysis
Merck & Co., Inc. (NYSE: MRK) Q3 2026 Earnings Summary
Merck & Co., Inc. furnished a Form 8-K covering Item 2.02 (Results of Operations and Financial Condition), reporting financial performance for the third quarter of 2026.
Key Financial Metrics
- Worldwide Sales: $18.085 billion, an increase of 5% (4% ex-FX) compared to $17.276 billion in Q3 2025.
- GAAP EPS: $2.04, down 12% compared to $2.32 in Q3 2025.
- Non-GAAP EPS: $2.49, down 3% compared to $2.58 in Q3 2025.
- One-Time Items: Q3 2026 results include a $0.12 per share charge related to a global license agreement with SciBrunch Therapeutics Co., Ltd.
Top Product Performance
- KEYTRUDA / KEYTRUDA QLEX: $8.601 billion (+6% YoY), including $830 million from KEYTRUDA QLEX.
- GARDASIL / GARDASIL 9: $1.995 billion (+14% YoY), supported by public-sector demand and pricing.
- WINREVAIR: $694 million (+93% YoY), exhibiting strong commercial launch momentum.
- Animal Health: $1.676 billion (+4% YoY), led by growth across both livestock and companion animal segments.
- Declines: JANUVIA/JANUMET fell 39% to $380 million and BRIDION dropped 67% to $144 million due to generic competition following patent expirations.
Full-Year 2026 Outlook
- Worldwide Sales: Narrowed and raised midpoint to $66.8 billion – $67.3 billion.
- Non-GAAP EPS: Narrowed and raised to $2.77 – $2.82, inclusive of the $0.12 per share SciBrunch charge.
Get Real-Time Alerts
Join our community to receive instant notifications when high-significance filings are published
Important Disclaimer
This content is drawn from public SEC filings and may contain errors. It is for informational purposes only and is not investment, legal, or tax advice.
Nothing here is a recommendation to buy, sell, or hold any security. Do your own due diligence.